Fully licensed, export-ready Colombian cultivation and processing platform with GACP certification, EU-GMP Part I approval, and established EU distribution access. Proven export execution with ~1 tonne already shipped into European medical markets; includes advanced processing infrastructure and PLC 2500 purification system.
Unbeatable Production Arbitrage
- UltraLow Costs: Allin production costs of €0.30 per gram, with further downward pressure expected as the facility scales toward its 25+ tonne licensed capacity.
- Elite Genetics: Proven highTHC cultivars (mid20% THC) featuring advanced terpene profiles tailored for European and Australian markets.
- Ideal Climate: Located in a premium microclimate with stable, predictable conditions enabling yearround cultivation.
Institutional-Grade Infrastructure & Scalability
- Immediate Capacity: 1.7 hectares of interconnected greenhouses currently producing 5.7 tonnes of dried flower annually.
- Expansion Ready: Fully licensed 15hectare site with capacity for 25+ tonnes, enabling significant scaleup with minimal additional capex.
- Operational Autonomy: Dedicated onsite power substation with diesel backup and a 20,000 m³ rainwater reservoir supported by a sophisticated water treatment system.
Advanced Post-Harvest & Processing Technology
- DualTrack Facility: Separate buildings for GACP postharvest and EUGMP / TGA GMPcompliant processing.
- Unique Technology Edge: Includes Colombia’s only PLC 2500 purification system and an Xray sterilization unit required for the Australian market.
- OnSite Laboratory: Fully equipped lab enabling realtime potency and purity testing to ensure pharmaceuticalgrade standards.
Validated Global Export Track Record
- Proven Market Access: One of the few Colombian producers with established exports; approximately 1 tonne already delivered to European markets.
- DeRisked Revenue: Sale includes a binding 3year offtake agreement and established distribution relationships in Germany and the UK.
Turnkey Transition & Strategic Value
- Investment Value: Over USD $12M already invested in infrastructure, licensing, and elite genetics.
- Financial Status: Debtfree; all relatedparty debt is forgiven at closing.
- Shortcut to Market: Bypasses the typical 3year development cycle including site selection, construction, and regulatory approvals in Colombia.
- Management Continuity: Core leadership team, including production specialists, will remain to ensure a seamless operational transition.
- Tax Efficiency: Tax loss carryforwards (~USD $1.5M) available through 2036, preserved under the share sale structure.
Currency: USD
Target Price / Revenue: TBD
Target Price / EBITDA: TBD
